Agitation Relapse Delayed With Dextromethorphan-Bupropion
(MedPage Today) -- DENVER -- Dextromethorphan-bupropion (known as AXS-05) delayed time to relapse in patients with Alzheimer's-related agitation, according to a phase III trial presented here.
Compared with placebo, AXS-05 increased the time... (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - April 17, 2024 Category: Psychiatry Source Type: news
GI Adverse Events Increased With Use of GLP-1 Agonists for Weight Loss
FRIDAY, Oct. 6, 2023 -- Use of glucagon-like peptide 1 (GLP-1) receptor agonists for weight loss is associated with increased risks for pancreatitis, gastroparesis, and bowel obstruction compared with use of bupropion-naltrexone, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 6, 2023 Category: Pharmaceuticals Source Type: news
GLP-1 Agonists Linked to Higher Risk for GI Complications GLP-1 Agonists Linked to Higher Risk for GI Complications
Compared with naltrexone/bupropion for weight loss, semaglutide and liraglutide were associated with a higher risk for three adverse gastrointestinal outcomes.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - October 5, 2023 Category: Drugs & Pharmacology Tags: Gastroenterology News Source Type: news
La FDA revisa la descripci ón de los efectos secundarios para la salud mental de los medicamentos para dejar de fumar Chantix (vareniclina) y Zyban (bupropión) para reflejar las conclusiones de estudio clínico
FDA revises description of mental health side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 25, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Drug Safety Communication: FDA revises description of mental health side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings
An FDA review found the side effects on mood, behavior, or thinking with the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) are lower than previously suspected. These risks still exist, but we believe the benefits of quitting smoking outweigh them. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 11, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Prolonged Antidepressant Treatment No Benefit in Bipolar I Disorder
THURSDAY, Aug. 3, 2023 -- For patients with bipolar I disorder who had recently had remission of a depressive episode, adjunctive treatment with escitalopram or bupropion XL that continues for 52 weeks does not show a significant benefit compared... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 3, 2023 Category: Pharmaceuticals Source Type: news
A New Genetic Test Could Determine Which Weight Loss Drug Will Actually Work For You
As popular as the latest drugs being touted for weight loss, including Ozempic, Mounjaro, and Wegovy, are on social media, like any medications, they don’t work in the same way for everyone. Not all are even approved to treat obesity, but are being used off label as a relatively easy way to shed pounds. While some users lose up to 20% or more of their body weight on these drugs, others struggle to shed single digit percentages.
That shouldn’t come as a surprise, since obesity isn’t a monolith and the factors that contribute to extra pounds are different for different people. In the same way that cancer do...
Source: TIME: Health - June 30, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate Weight loss Source Type: news
Adaptation to Pharmacotherapy Does Not Up Smoking Cessation in Black Adults
TUESDAY, June 27, 2023 -- For Black adults who smoke, adaptation to varenicline and/or bupropion plus nicotine patch (NP) does not improve abstinence rates compared with NP monotherapy, according to a study published online June 20 in JAMA Network... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 27, 2023 Category: Pharmaceuticals Source Type: news
The role of decision tree and machine learning models for outcome prediction of bupropion exposure: a nationwide analysis of more than 14,000 patients in the United States - Mehrpour O, Saeedi F, Vohra V, Abdollahi J, Shirazi FM, Goss F.
Bupropion is widely used for the treatment of major depressive disorder and for smoking cessation assistance. Unfortunately, there are no practical systems to assist clinicians or poison centers in predicting outcomes based on clinical features. Hence, the... (Source: SafetyLit)
Source: SafetyLit - March 28, 2023 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Improvement of depressive symptoms, after a suicide attempt, with dextromethorphan/bupropion combination treatment in a patient with treatment-resistant depression and psychiatric comorbidities - Pedraz-Petrozzi B, Deuschle M, Gilles M.
We admitted a 42-year-old patient with severe treatment-resistant depression and with psychiatric comorbidities. The patient attempted suicide 5 weeks after admission. Subsequently, we initiated dextromethorphan/bupropion based on prior evidence. As a re... (Source: SafetyLit)
Source: SafetyLit - March 20, 2023 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news
Monthly News Roundup - August 2022
FDA Approves Auvelity, a Novel and Rapid-Acting Antidepressant
In August, the FDA approved Auvelity (dextromethorphan and bupropion) extended-release tablets for the treatment of major depressive disorder (MDD) in adults. Auvelity, from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 31, 2022 Category: Pharmaceuticals Source Type: news
FDA Approves'Rapid-Acting' Oral Drug for Major Depression FDA Approves'Rapid-Acting' Oral Drug for Major Depression
The US Food and Drug Administration has approved dextromethorphan-bupropion (Auvelity), the first for an NMDA receptor antagonist for the treatment of major depressive disorder in adults.FDA Approvals (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - August 22, 2022 Category: Internal Medicine Tags: Psychiatry News Alert Source Type: news
FDA Approves Auvelity (dextromethorphan and bupropion) for the Treatment of Major Depressive Disorder in Adults
Auvelity is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared to placebo starting at one week11-4
Auvelity uses the first new oral mechanism of action... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 20, 2022 Category: Drugs & Pharmacology Source Type: news
FDA OKs First Oral NMDA Receptor Antagonist for Depression
(MedPage Today) -- The FDA approved combination dextromethorphan and bupropion extended-release tablets (Auvelity) for adults with major depressive disorder (MDD), Axsome Therapeutics announced on Friday.
Dextromethorphan-bupropion is an oral... (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - August 19, 2022 Category: Psychiatry Source Type: news
Granules India gets USFDA nod for generic antidepressant drug
"We are pleased to receive approval of Bupropion Hydrochloride (XL) tablet product within first review cycle of 10 months from filing date. This product will be a valuable addition to our growing modified release product portfolio in the US market," GPI Executive Director Priyanka Chigurupati stated. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 3, 2022 Category: Pharmaceuticals Source Type: news
